In 2012 UBC CPD received the Royal College Accredited CPD Provider Innovation Award for This Changed My Practice.
Dr. Monica Beaulieu
New study on the use of erythropoietin stimulating agents in chronic kidney disease has made us evaluate the risk-benefit of ESA’s in CKD patients not on dialysis.
By Dr. Monica Beaulieu on June 14, 2010
The evidence strongly suggests that there is little to no benefit gained by raising the Hb over > 100g/L (and perhaps even lower) in diabetic patients with CKD not on dialysis.